Position in SYRE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$19,975,500
+$14,931,500 QoQ
Shares Held
225,000
+125.0% QoQ
Ownership
0.255%
of shares outstanding
% of Portfolio
0.81%
of 13F equity value
Holder Rank
#53
of 267 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SEVEN GRAND MANAGERS, LLC holds $220,302,823 across 50 Biotechnology names. SYRE ranks #1 (9.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SYRE |
Spyre Therapeutics, Inc.
This page
|
225,000 | $19,975,500 | |
| 2 | NKTR |
Nektar Therapeutics
|
240,000 | $16,754,400 | |
| 3 | MANE |
Veradermics, Inc
|
125,000 | $15,367,500 | |
| 4 | APGE |
Apogee Therapeutics, Inc.
|
100,000 | $13,273,000 | |
| 5 | ABVX |
Abivax S.A.
|
90,000 | $11,993,400 | |
| 6 | DFTX |
Definium Therapeutics, Inc.
|
225,000 | $10,584,000 | |
| 7 | ORKA |
Oruka Therapeutics, Inc.
|
110,000 | $10,468,700 | |
| 8 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
100,000 | $9,748,000 |
All Filings in SYRE
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19,975,500 | 225,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $5,044,000 | 100,000 | Shares | Sole | 2026-05-06 | |
| 2025-12-31 | $3,276,000 | 100,000 | Shares | Sole | 2026-02-10 | |
| No filing history on record for this holder in this stock. | ||||||